Hearts & Science: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Hearts & Science
Largest movements
- Receivables within one year +€2.5m
up €2.5m (+192.1%), from €1.3m to €3.7m
of which Trade receivables: +€2.0m
- Cash -€189,051
no longer reported in 2025 (was €189,051)
mainly Receivables within one year (-€2.5m) and Advances received (-€51,351)
- Trade debts +€2.1m
up €2.1m (+142.0%), from €1.5m to €3.6m
- Profit (loss) carried forward +€134,691
up €134,691 (+93.0%), from -€144,819 to -€10,128
- Tax, wage and social debts +€101,071
up €101,071 (+114.5%), from €88,302 to €189,373
- Advances received -€51,351
no longer reported in 2025 (was €51,351)
- Gross operating margin +€40,794
up €40,794 (+74.6%), from €54,679 to €95,472
- Financial income +€15,524
up €15,524 (+63.4%), from €24,502 to €40,026
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,470,338 | €3,742,868 | +€2.3m | +154.6% |
| Current assets | 29/58 | €1,470,338 | €3,742,868 | +€2.3m | +154.6% |
| Amounts receivable within one year | 40/41 | €1,281,286 | €3,742,868 | +€2.5m | +192.1% |
| Trade receivables | 40 | €1,281,286 | €3,309,240 | +€2.0m | +158.3% |
| Other amounts receivable | 41 | - | €433,628 | +€433,628 | |
| Cash at bank and in hand | 54/58 | €189,051 | - | -€189,051 | |
| Total equity and liabilities | 10/49 | €1,470,338 | €3,742,868 | +€2.3m | +154.6% |
| Equity | 10/15 | -€139,819 | -€5,128 | +€134,691 | +96.3% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€144,819 | -€10,128 | +€134,691 | +93.0% |
| Amounts payable | 17/49 | €1,610,156 | €3,747,996 | +€2.1m | +132.8% |
| Amounts payable within one year | 42/48 | €1,610,156 | €3,747,996 | +€2.1m | +132.8% |
| Trade debts | 44 | €1,470,504 | €3,558,623 | +€2.1m | +142.0% |
| Suppliers | 440/4 | €1,470,504 | €3,558,623 | +€2.1m | +142.0% |
| Advances received on contracts in progress | 46 | €51,351 | - | -€51,351 | |
| Taxes, remuneration and social security | 45 | €88,302 | €189,373 | +€101,071 | +114.5% |
| Taxes | 450/3 | €88,302 | €189,373 | +€101,071 | +114.5% |
| Other operating charges | 640/8 | €190 | - | -€190 | |
| Gross operating margin | 9900 | €54,679 | €95,472 | +€40,794 | +74.6% |
| Operating profit (loss) | 9901 | €54,489 | €95,472 | +€40,984 | +75.2% |
| Financial income | 75/76B | €24,502 | €40,026 | +€15,524 | +63.4% |
| Recurring financial income | 75 | €24,502 | €40,026 | +€15,524 | +63.4% |
| Financial charges | 65/66B | €650 | €808 | +€158 | +24.3% |
| Recurring financial charges | 65 | €650 | €808 | +€158 | +24.3% |
| Profit (loss) for the period before taxes | 9903 | €78,341 | €134,691 | +€56,350 | +71.9% |
| Profit (loss) for the period | 9904 | €78,341 | €134,691 | +€56,350 | +71.9% |
| Profit (loss) for the period to be appropriated | 9905 | €78,341 | €134,691 | +€56,350 | +71.9% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 10 October 2026 via checked.be.